| Year |
Citation |
Score |
| 2023 |
Lu X, Zhong L, Lindell E, Veanes M, Guo J, Zhao M, Salehi M, Swartling FJ, Chen X, Sjöblom T, Zhang X. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death & Disease. 14: 676. PMID 37833290 DOI: 10.1038/s41419-023-06204-1 |
0.43 |
|
| 2023 |
Mainwaring OJ, Weishaupt H, Zhao M, Rosén G, Borgenvik A, Breinschmid L, Verbaan AD, Richardson S, Thompson D, Clifford SC, Hill RM, Annusver K, Sundström A, Holmberg KO, Kasper M, ... ... Swartling FJ, et al. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nature Communications. 14: 1221. PMID 36869047 DOI: 10.1038/s41467-023-36847-9 |
0.532 |
|
| 2022 |
Borgenvik A, Holmberg KO, Bolin S, Zhao M, Savov V, Rosén G, Hutter S, Garancher A, Suryo Rahmanto A, Bergström T, Olsen TK, Mainwaring OJ, Sattanino D, Verbaan AD, Rusert JM, ... ... Swartling FJ, et al. Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma. Cancer Research. PMID 36219398 DOI: 10.1158/0008-5472.CAN-22-2108 |
0.506 |
|
| 2022 |
Weishaupt H, Čančer M, Rosén G, Holmberg KO, Häggqvist S, Bunikis I, Jiang Y, Sreedharan S, Gyllensten U, Becher OJ, Uhrbom L, Ameur A, Swartling FJ. Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. Neuro-Oncology. PMID 35738865 DOI: 10.1093/neuonc/noac158 |
0.311 |
|
| 2022 |
Trieu KG, Tsai SY, Eberl M, Ju V, Ford NC, Doane OJ, Peterson JK, Veniaminova NA, Grachtchouk M, Harms PW, Swartling FJ, Dlugosz AA, Wong SY. Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease. Cell Reports. 39: 110779. PMID 35508126 DOI: 10.1016/j.celrep.2022.110779 |
0.351 |
|
| 2021 |
Adolphe C, Millar A, Kojic M, Barkauskas DS, Sundstrom A, Swartling FJ, Hediyeh-Zadeh S, Tan CW, Davis MJ, Genovesi LA, Wainwright BJ. SOX9 defines distinct populations of cells in SHH medulloblastoma but is not required for Math1-driven tumour formation. Molecular Cancer Research : McR. PMID 34330843 DOI: 10.1158/1541-7786.MCR-21-0117 |
0.43 |
|
| 2021 |
Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, ... ... Swartling FJ, et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Journal For Immunotherapy of Cancer. 9. PMID 34083417 DOI: 10.1136/jitc-2020-002181 |
0.698 |
|
| 2021 |
Berg TJ, Marques C, Pantazopoulou V, Johansson E, von Stedingk K, Lindgren D, Jeannot P, Pietras EJ, Bergström T, Swartling FJ, Governa V, Bengzon J, Belting M, Axelson H, Squatrito M, et al. The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2. Cancer Research. PMID 33483373 DOI: 10.1158/0008-5472.CAN-20-1785 |
0.431 |
|
| 2021 |
Mainwaring O, Weishaupt H, Hutter S, Zhao M, Rosén G, Breinschmid L, Verbaan A, Sundström A, Annusver K, Kasper M, Swartling F. EMBR-07. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA BY ARF PATHWAY SUPPRESSION Neuro-Oncology. 23: i7-i7. DOI: 10.1093/neuonc/noab090.025 |
0.49 |
|
| 2020 |
Borgenvik A, Čančer M, Hutter S, Swartling FJ. Targeting MYCN in Molecularly Defined Malignant Brain Tumors. Frontiers in Oncology. 10: 626751. PMID 33585252 DOI: 10.3389/fonc.2020.626751 |
0.46 |
|
| 2020 |
Morgan D, Studham M, Tjärnberg A, Weishaupt H, Swartling FJ, Nordling TEM, Sonnhammer ELL. Perturbation-based gene regulatory network inference to unravel oncogenic mechanisms. Scientific Reports. 10: 14149. PMID 32843692 DOI: 10.1038/S41598-020-70941-Y |
0.334 |
|
| 2020 |
Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, ... ... Swartling FJ, et al. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proceedings of the National Academy of Sciences of the United States of America. 117: 20127-20138. PMID 32747535 DOI: 10.1073/Pnas.1920521117 |
0.612 |
|
| 2020 |
Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, ... ... Swartling FJ, et al. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. Cell Reports. 32: 107897. PMID 32668248 DOI: 10.1016/J.Celrep.2020.107897 |
0.459 |
|
| 2020 |
Xiong A, Roy A, Spyrou A, Weishaupt H, Marinescu VD, Olofsson T, Hermanson O, Swartling FJ, Forsberg-Nilsson K. Nuclear Receptor Binding Protein 2 Is Downregulated in Medulloblastoma, and Reduces Tumor Cell Survival upon Overexpression. Cancers. 12. PMID 32517178 DOI: 10.3390/Cancers12061483 |
0.575 |
|
| 2020 |
Bolin S, Savov V, Borgenvik A, Rosén G, Olausson KH, Zhao M, Garancher A, Rahmanto AS, Hutter S, Mainwaring O, Rusert J, Sundstrom A, Richardson S, Fotaki G, Hill RM, ... ... Swartling FJ, et al. MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE Neuro-Oncology. 22: iii400-iii400. DOI: 10.1093/neuonc/noaa222.528 |
0.483 |
|
| 2019 |
Čančer M, Hutter S, Holmberg KO, Rosén G, Sundström A, Tailor J, Bergström T, Garancher A, Essand M, Wechsler-Reya RJ, Falk A, Weishaupt H, Swartling FJ. Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. Cell Stem Cell. 25: 855-870.e11. PMID 31786016 DOI: 10.1016/J.Stem.2019.10.005 |
0.64 |
|
| 2019 |
Čančer M, Drews LF, Bengtsson J, Bolin S, Rosén G, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Weishaupt H, Swartling FJ. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death & Disease. 10: 881. PMID 31754113 DOI: 10.1038/S41419-019-2120-1 |
0.488 |
|
| 2019 |
Huang M, Tailor J, Zhen Q, Gillmor AH, Miller ML, Weishaupt H, Chen J, Zheng T, Nash EK, McHenry LK, An Z, Ye F, Takashima Y, Clarke J, Ayetey H, ... ... Swartling FJ, et al. Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell. PMID 31204176 DOI: 10.1016/J.Stem.2019.05.013 |
0.766 |
|
| 2019 |
Bolin S, Savov V, Borgenvik A, Rosen G, Garancher A, Rahmanto AS, Hutter S, Mainwaring O, Olausson KH, Rusert J, Sundstrom A, Richardson S, Fotaki G, Hill R, Dubuc A, ... ... Swartling F, et al. MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE Neuro-Oncology. 21: ii108-ii109. DOI: 10.1093/Neuonc/Noz036.185 |
0.595 |
|
| 2019 |
Mainwaring O, Weishaupt H, Hutter S, Rosen G, Annusver K, Kasper M, Swartling F. Medu-16. Myc But Not Mycn Generates Aggressive Group 3 Medulloblastoma Through Arf Suppression Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.175 |
0.306 |
|
| 2018 |
Wallmann T, Zhang XM, Wallerius M, Bolin S, Joly AL, Sobocki C, Leiss L, Jiang Y, Bergh J, Holland EC, Enger PØ, Andersson J, Swartling FJ, Miletic H, Uhrbom L, et al. Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. Iscience. 9: 71-83. PMID 30384135 DOI: 10.1016/J.Isci.2018.10.011 |
0.53 |
|
| 2018 |
Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom L. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. The Journal of Pathology. PMID 30357839 DOI: 10.1002/Path.5186 |
0.462 |
|
| 2018 |
Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, et al. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4121. PMID 30297829 DOI: 10.1038/S41467-018-06564-9 |
0.423 |
|
| 2018 |
Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJ. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene. PMID 29511348 DOI: 10.1038/S41388-018-0135-1 |
0.653 |
|
| 2018 |
Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, ... ... Swartling FJ, et al. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition. Brain : a Journal of Neurology. PMID 29490009 DOI: 10.1093/Brain/Awy039 |
0.686 |
|
| 2018 |
Čančer M, Drews L, Rosén G, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Weishaupt H, Swartling F. Exth-65. Bet Inhibition In Combination With Temozolomide Targets Mycn-Positive Glioblastoma Cells Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.412 |
0.398 |
|
| 2018 |
Bolin S, Savov V, Borgenvik A, Garancher A, Rosén G, Rahmanto A, Hutter S, Rusert J, Garzia L, Fotaki G, Hill RM, Dubuc AM, Remke M, aner M, Ramaswamy V, ... ... Swartling F, et al. TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE? Neuro-Oncology. 20: vi276-vi276. DOI: 10.1093/Neuonc/Noy148.1147 |
0.387 |
|
| 2018 |
Hutter S, Weishaupt H, Rosén G, Swartling F. Tmod-28. Myc Overexpression Drives Medulloblastoma From Human Neuroepithelial Stem Cells Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1140 |
0.464 |
|
| 2017 |
Neumann JE, Swartling FJ, Schüller U. Medulloblastoma: experimental models and reality. Acta Neuropathologica. 134: 679-689. PMID 28725965 DOI: 10.1007/S00401-017-1753-3 |
0.406 |
|
| 2017 |
Roy A, Libard S, Weishaupt H, Gustavsson I, Uhrbom L, Hesselager G, Swartling FJ, Pontén F, Alafuzoff I, Tchougounova E. Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential. Frontiers in Oncology. 7: 115. PMID 28626727 DOI: 10.3389/Fonc.2017.00115 |
0.486 |
|
| 2017 |
Roy A, Attarha S, Weishaupt H, Edqvist PH, Swartling FJ, Bergqvist M, Siebzehnrubl FA, Smits A, Pontén F, Tchougounova E. Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression. Oncotarget. 8: 24815-24827. PMID 28445977 DOI: 10.18632/Oncotarget.15820 |
0.429 |
|
| 2017 |
Hutter S, Bolin S, Weishaupt H, Swartling FJ. Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes. 8. PMID 28333115 DOI: 10.3390/Genes8040107 |
0.572 |
|
| 2017 |
Suryo Rahmanto A, Swartling FJ, Sangfelt O. Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence. Molecular & Cellular Oncology. 4: e1252871. PMID 28197531 DOI: 10.1080/23723556.2016.1252871 |
0.51 |
|
| 2017 |
Bolin S, Borgenvik A, Persson C, Sundström A, Qi J, Bradner J, Weiss W, Cho Y, Weishaupt H, Swartling F. PDTM-34. COMBINED BET BROMODOMAIN AND CDK2 INHIBITION IN MYC-DRIVEN MEDULLOBLASTOMA Neuro-Oncology. 19: vi197-vi197. DOI: 10.1093/Neuonc/Nox168.797 |
0.512 |
|
| 2017 |
Xie Y, Sundström A, Tan E, Marinescu VD, Maturi NP, Tirfing M, Blokzijl A, Jin C, Chen L, Essand M, Swartling F, Nelander S, Jiang Y, Uhrbom L. CBIO-25. HIGH EXPRESSION OF LGR5 MAINTAINS GLIOBLASTOMA STEM CELLS IN A PRONEURAL STATE AND PROMOTES SELF-RENEWAL AND INVASION Neuro-Oncology. 19: vi37-vi37. DOI: 10.1093/Neuonc/Nox168.143 |
0.393 |
|
| 2017 |
Bolin S, Savov V, Borgenvik A, Garancher A, Rosén G, Rahmanto AS, Hutter S, Rusert J, Fotaki G, Hill R, Dubuc A, Remke M, Čančer M, Ramaswamy V, Clifford S, ... ... Swartling F, et al. TMOD-31. RARE SOX9+ CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE Neuro-Oncology. 19: vi260-vi261. DOI: 10.1093/Neuonc/Nox168.1068 |
0.403 |
|
| 2017 |
Huang M, Tailor JK, Zhen Q, Nash EK, Phillips J, Morrissy S, Kool M, Pfister SM, Swartling FJ, Taylor MD, Smith A, Weiss WA. TMOD-11. HUMAN STEM CELL BASED MODEL OF MEDULLOBLASTOMA Neuro-Oncology. 19: vi256-vi257. DOI: 10.1093/Neuonc/Nox168.1050 |
0.774 |
|
| 2017 |
Čančer M, Hutter S, Rosén G, Hellström A, Essand M, Huang M, Tailor J, Smith A, Weiss WA, Falk A, Weishaupt H, Swartling F. TMOD-05. MYCN OVEREXPRESSION AND STABILIZATION DRIVES MEDULLOBLASTOMA FROM HUMAN NEURO-EPITHELIAL STEM CELLS Neuro-Oncology. 19: vi255-vi255. DOI: 10.1093/Neuonc/Nox168.1044 |
0.779 |
|
| 2016 |
Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S, Alafuzoff I, Weishaupt H, Fryknäs M, Larsson R, Swartling F, Uhrbom L. Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype. Cancer Research. PMID 28115362 DOI: 10.1158/0008-5472.Can-16-2482 |
0.613 |
|
| 2016 |
Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, Rosén G, Čančer M, Hutter S, Sundström A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Cho YJ, ... ... Swartling FJ, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. The Embo Journal. PMID 27625374 DOI: 10.15252/Embj.201693889 |
0.492 |
|
| 2016 |
Truvé K, Dickinson P, Xiong A, York D, Jayashankar K, Pielberg G, Koltookian M, Murén E, Fuxelius HH, Weishaupt H, Swartling FJ, Andersson G, Hedhammar Å, Bongcam-Rudloff E, Forsberg-Nilsson K, et al. Utilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development-Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus. Plos Genetics. 12: e1006000. PMID 27171399 DOI: 10.1371/Journal.Pgen.1006000 |
0.401 |
|
| 2016 |
Cancer M, Weishaupt H, Rosen G, Bunikis I, Jiang Y, Sreedharan S, Bolin S, Gyllensten U, Becher OJ, Uhrbom L, Ameur A, Swartling FJ. Abstract 2688: A forward genetics screen of murine brain tumors identifies novel candidate genes involved in gliomagenesis Cancer Research. 76: 2688-2688. DOI: 10.1158/1538-7445.Am2016-2688 |
0.496 |
|
| 2016 |
Bolin S, Borgenvik A, Persson C, Rosén G, Sundström A, Qi J, Bradner JE, Weiss WA, Cho Y, Weishaupt H, Swartling FJ. Abstract 2473: Combined BET-bromodomain and CDK2 inhibition in MYC-driven medulloblastoma Cancer Research. 76: 2473-2473. DOI: 10.1158/1538-7445.Am2016-2473 |
0.672 |
|
| 2015 |
Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud FI, ... ... Swartling FJ, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 27: 72-84. PMID 25533335 DOI: 10.1016/J.Ccell.2014.11.002 |
0.723 |
|
| 2015 |
Swartling FJ, Čančer M, Frantz A, Weishaupt H, Persson AI. Deregulated proliferation and differentiation in brain tumors. Cell and Tissue Research. 359: 225-54. PMID 25416506 DOI: 10.1007/S00441-014-2046-Y |
0.718 |
|
| 2014 |
Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, ... ... Swartling FJ, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 912-25. PMID 24297863 DOI: 10.1158/1078-0432.Ccr-13-2281 |
0.603 |
|
| 2014 |
Hede SM, Savov V, Weishaupt H, Sangfelt O, Swartling FJ. Oncoprotein stabilization in brain tumors. Oncogene. 33: 4709-21. PMID 24166497 DOI: 10.1038/Onc.2013.445 |
0.605 |
|
| 2014 |
Swartling FJ, Bolin S, Phillips JJ, Persson AI. Signals that regulate the oncogenic fate of neural stem cells and progenitors. Experimental Neurology. 260: 56-68. PMID 23376224 DOI: 10.1016/J.Expneurol.2013.01.027 |
0.726 |
|
| 2014 |
Meyerowitz JG, Gustafson WC, Nekritz E, Swartling F, Shokat KM, Ruggero D, Weiss WA. Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B78 |
0.798 |
|
| 2014 |
Hill RM, Kuijper S, Lindsey J, Schwalbe EC, Barker K, Boult J, Williamson D, Ahmad Z, Hallsworth A, Ryan S, Poon E, Robinson S, Ruddle R, Raynaud F, Howell L, ... ... Swartling FJ, et al. MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-201 |
0.713 |
|
| 2014 |
Savov V, Fotaki G, Remke M, Dubuc AM, Ramaswamy V, Cancer M, Weishaupt H, Taylor MD, Swartling FJ. Abstract 996: Metastasis and tumor recurrence from rare SOX9-positive cells in Group 4 medulloblastoma Cancer Research. 74: 996-996. DOI: 10.1158/1538-7445.Am2014-996 |
0.611 |
|
| 2014 |
Bolin SM, Lau J, Chen J, Savov V, Persson AI, Hede S, Weiss WA, Swartling F. Abstract 3100: Glial origin for MYCN-driven medulloblastoma and targeted prosenescence therapies Cancer Research. 74: 3100-3100. DOI: 10.1158/1538-7445.Am2014-3100 |
0.827 |
|
| 2014 |
Swartling FJ, Savov V, Čančer M, Bolin S, Fotaki G, Dubuc A, Remke M, Ramaswamy V, Weishaupt H, Taylor MD. Metastasis And Tumor Recurrence From Rare Sox9-Positive Cells In Mycn-Driven Medulloblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.20 |
0.525 |
|
| 2014 |
Vaidyanathan G, Gururangan S, Bigner D, Zalutsky M, Morfouace M, Shelat A, Megan J, Freeman BB, Robinson S, Throm S, Olson JM, Li X, Guy KR, Robinson G, Stewart C, ... ... Swartling F, ... ... Swartling FJ, et al. MEDULLOBLASTOMA Neuro-Oncology. 16: i71-i96. DOI: 10.1093/Neuonc/Nou074 |
0.66 |
|
| 2013 |
Swartling FJ, Hede SM, Weiss WA. What underlies the diversity of brain tumors? Cancer Metastasis Reviews. 32: 5-24. PMID 23085857 DOI: 10.1007/S10555-012-9407-3 |
0.681 |
|
| 2013 |
Bolin S, Lau J, Savov V, Chen J, Persson AI, Hede S, Weiss WA, Swartling FJ. Abstract 357: A glial origin for medulloblastoma and inhibition of MYCN stabilization. Cancer Research. 73: 357-357. DOI: 10.1158/1538-7445.Am2013-357 |
0.823 |
|
| 2012 |
Põlajeva J, Swartling FJ, Jiang Y, Singh U, Pietras K, Uhrbom L, Westermark B, Roswall P. miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma. Bmc Cancer. 12: 378. PMID 22931209 DOI: 10.1186/1471-2407-12-378 |
0.436 |
|
| 2012 |
Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21: 601-13. PMID 22624711 DOI: 10.1016/J.Ccr.2012.04.012 |
0.775 |
|
| 2012 |
Swartling FJ. Myc proteins in brain tumor development and maintenance. Upsala Journal of Medical Sciences. 117: 122-31. PMID 22348395 DOI: 10.3109/03009734.2012.658975 |
0.555 |
|
| 2011 |
Roswall P, Põlajeva J, Swartling FJ, Jiang Y, Singh U, Uhrbom L, Westermark B. Abstract 3985: MicroRNA-21 regulates Sox2 expression and tumor self-renewal in PDGF-driven glioma Cancer Research. 71: 3985-3985. DOI: 10.1158/1538-7445.Am2011-3985 |
0.46 |
|
| 2011 |
Swartling FJ, Persson AI, Lau J, Northcott PA, Grimmer MR, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells Cancer Research. 71: 3451-3451. DOI: 10.1158/1538-7445.Am2011-3451 |
0.817 |
|
| 2010 |
Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell. 18: 669-82. PMID 21156288 DOI: 10.1016/J.Ccr.2010.10.033 |
0.772 |
|
| 2010 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510 |
0.791 |
|
| 2009 |
Swartling FJ, Ferletta M, Kastemar M, Weiss WA, Westermark B. Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene. 28: 3121-3131. PMID 19543319 DOI: 10.1038/Onc.2009.168 |
0.655 |
|
| 2008 |
Swartling FJ. Identifying candidate genes involved in brain tumor formation Upsala Journal of Medical Sciences. 113: 1-38. PMID 18521796 DOI: 10.3109/2000-1967-215 |
0.559 |
|
| Show low-probability matches. |